# Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer

> **NCT03340558** · PHASE2 · WITHDRAWN · sponsor: **Niharika Mettu**

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT03340558
- **Lead sponsor:** Niharika Mettu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-05
- **Primary completion:** 2021-02
- **Final completion:** 2025-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Negative results in a similar study
- **Last updated:** 2018-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03340558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03340558, "Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03340558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*